Biocon Ltd Share Price

Q: What is the share price of Biocon Ltd today?

Biocon Ltd share price as on 22 Jan 2025 is ₹385.2

Biotechnology

NSE: BIOCON Mid Cap ISIN: INE376G01013

As on 22 January 2025 at 09:49 IST

₹385.20

-5.35

(-1.37%)

Sell Buy

About Biocon Ltd

Biocon Ltd. was established in 1978 and is a leading biopharmaceutical company. It was established by Kiran Mazumdar-Shaw in 1978. With decades of experience, Biocon has made strides in developing and manufacturing affordable biosimilars. The headquarters of the company is located in Bengaluru, Karnataka, India. Biocon operates in the biopharmaceutical sector, and has carved out a niche for itself with its innovative products. The company’s main offerings include biosimilars such as Insugen, Basalog, and CANMAb. Along with that, they also provide generic formulations and novel biologics. Read More...

Over 1 Month

18.51%

Over 6 Months

16.46%

Over 1 Year

48.78%

Over 3 Years

3.57%

Biocon Ltd Summary

Close ₹ 385.20

Open ₹ 390.55

High ₹ 392.35

Low ₹ 382.65

Volume 6,64,217

Net Turnover (in ₹) ₹ 1,85,91,88,748.75

52Wk High ₹ 404.70

52Wk Low ₹ 244.55

52Wk High / Low

244.55

404.70

Biocon Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 46,889.43

EPS (TTM) 0.35

Book Value (BV) 90.70

Div. Yield 0.13 %

P/E (TTM) 1,115.14

Price/Book Value 4.30

Delivery % 30.25 %

Face Value 5

Key Ratios

PE Ratio 266.77

PB Ratio 2.91

EV to Sales 15.59

PEG Ratio -2.78

ROA 0.91

ROE 0.97

Debt-Equity 0.15

Net Profit Margin 4.98

Operating Profit Margin 21.31

Biocon Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	15,621.20	11,550.10	8,396.70	7,397.60	6,461.90
Total Expenses	14,000.20	10,194.60	7,095.60	6,263.10	5,314.50
Profit Before Tax	1,525.20	897.10	983.10	1,067.70	1,214.90
Profit After Tax	1,297.80	643	771.60	846.20	899.80
Operating Profit after Depreciation	2,595.40	1,774.50	1,368.70	1,192.20	1,212.30

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	34,651.70	34,197.20	7,259.10	6,910.60	6,590.60
Total Non Current Assets	40,891.50	39,708.80	12,011.70	10,921.90	9,118.80
Total Current Assets	15,179.20	12,334	8,382.30	7,600.40	5,325
TOTAL ASSETS	56,070.70	52,042.80	20,394	18,522.30	14,443.80
Total Shareholder's Fund	19,783.70	17,866.90	8,432.50	7,626.90	6,705.80

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	2,953.90	1,852.50	1,176.60	1,159.70	1,283.10
Net Cash used in Investing Activities	-1,001.60	-14,260.10	-1,662	-3,651.40	-1,505.30
Net Cash used in Financing Activities	-2,332.70	13,048.70	242.10	2,564	387.60

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,320.30	2,264.30	1,925.40	2,178.60	2,190.10
Total Expenses	2,184.50	2,155.90	1,785.70	1,819.80	1,801.60
Profit Before Tax	150.30	2,971.20	139.70	358.80	548.20
Profit After Tax	119.30	2,848.40	86.10	280.50	436.30
Operating Profit after Depreciation	334.60	178	140.10	359.20	389.70

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	915	914	819.30	743.20	720.70
Total Non Current Assets	11,008.20	10,463.90	6,466.80	6,404.40	6,227.10
Total Current Assets	2,760	2,566	2,402.20	2,169.30	2,083.70
TOTAL ASSETS	13,768.20	13,029.90	8,869	8,573.70	8,310.80
Total Shareholder's Fund	10,912.30	10,916	8,092.90	7,907.10	7,537.30

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	-123.20	219.30	47.60	571.30	387.10
Net Cash used in Investing Activities	-294.70	-1,173.10	-302.10	-720.60	-188.90
Net Cash used in Financing Activities	343.60	1,039.40	112	27.80	-128.90

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	3,590.40	3,432.90	3,917.10	3,953.70	3,462.30
Total Expenses	2,905	2,812.50	3,003.90	3,051	2,744.90
Profit Before Tax	98.40	1,145.50	319	808.20	214.30
Profit After Tax	27.10	861.80	222.90	753.30	172.70
Operating Profit after Depreciation	717.90	1,754.90	961.80	1,468.20	875.30

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	525.40	510.60	532.60	562.80	518.70
Total Expenses	487.80	465.70	480.40	491.50	451.50
Profit Before Tax	20.90	1.10	21.80	32.90	46
Profit After Tax	3.20	0.90	14	24	34.70
Operating Profit after Depreciation	111.10	86.80	91.10	119.80	136.80

Biocon Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 384.97

S2 379.38

S3 369.52

Pivot 394.83

R1 400.42

R2 410.28

R3 415.87

Moving Average

20 SMA 372.25

50 SMA 359.65

100 SMA 355.69

200 SMA 340.58

Biocon Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Biocon Ltd

₹0.5/Share

Announcement Date 05 Jul 2024

Record Date 05 Jul 2024

Div Yield 10%

AGM Date: 28 Jul 2022

Financial Results for the quarter and year ended March 31, 2022 A.G.M (Revised) (As Per BSE Bulletin dated on 01.07.2022) With reference to our earlier letter dated April 28, 2022, we wish to inform you that the Board of Directors vide resolution passed through circulation on June 30, 2022 have approved for the change of date of 44th Annual General Meeting (AGM) of the Company from Friday, July 29, 2022 to Thursday, July 28, 2022. Accordingly, the 44th AGM of the Company will be held on Thursday, July 28, 2022 at 3:30 P.M. (IST) through Video Conferencing / Other AudioVisual Means (OAVM). A copy of the Notice convening the said AGM will be sent in due course. Kindly take the above information on record and acknowledge. (As Per BSE Announcement Dated on 01.07.2022) Annual Report (ESG Report encompassing Business Responsibility and Sustainability Report is a supplement to the Annual Report) of the Company for FY 2021-22 along with Notice of Annual General Meeting. (As Per BSE Announcement Dated on 05/07/2022) Outcome/Proceedings of AGM held on July 28, 2022 Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that the following appointments/re-appointments of the directors has been approved by the shareholders at the 44th Annual General Meeting ('AGM') of the Company, held on Thursday, July 28, 2022, through video conferencing. 1. Re-appointment of Ms. Kiran Mazumdar Shaw (DIN: 00347229) as director, liable to retire by rotation; 2. Appointment of Mr. Eric Vivek Mazumdar (DIN: 09381549) as a Non-Executive, Non-Independent Director of the Company; 3. Appointment of Ms. Naina Lal Kidwai (DIN: 00017806) as an Independent Director of the Company, for a term commencing from April 28, 2022 till the conclusion of the 47th AGM of the Company to be held in the year 2025. This intimation will also be available on website of the Company at www.biocon.com Voting results and scrutinizers' report of the 44th Annual General Meeting ('AGM') of the Company (As per BSE Announcement Dated on 29/07/2022) Biocon Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 30/07/2022)

AGM Date: 11 Aug 2023

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, May 23, 2023, inter alia, has considered the following: a)Financial results b)Recommendation of Final Dividend c)Annual General Meeting (AGM) and other matters Copies of newspaper advertisement published on July 18, 2023 in Financial Express (English Language) and Vijayavani (Kannada Language) intimating that 45th Annual General Meeting of the Company will be held on Friday, August 11, 2023 at 3:30 pm (IST) through Video Conferencing/Other Audio Visual Means. (As Per BSE Announcement dated on 18.07.2023) Copies of Newspaper Advertisement published on July 21, 2023 in Financial Express (English Language) and Vijayavani (Kannada Language) regarding Notice of 45th Annual General Meeting etc. (As Per BSE Announcement dated on 21.07.2023) Newspaper advertisement published on July 29, 2023 in Financial Express (English Language) and Vijayavani (Kannada Language) regarding Addendum to Notice of the 45th Annual General Meeting scheduled to be held on Friday, August 11, 2023. (As Per BSE Announcement Dated on 29.07.2023) Re-appointment and Appointment of Director at 45th Annual General Meeting of the Company Proceedings of 45th AGM held on August 11, 2023 at 3:30 PM (As Per BSE Announcement Dated on 11.08.2023)

AGM Date: 09 Aug 2024

Outcome of Board Meeting held on May 16, 2024 Newspaper Publication - Post AGM (As Per BSE Announcement dated on 19.07.2024) Proceedings of 46th AGM of the Company (As Per BSE Announcement Dated on: 08/08/2024) Voting results and Scrutinizer''s report (As Per Bse Announcement Dated on 13.08.2024)

Biocon Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Biocon Ltd	₹390.30	₹46,859.42
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Biocon Ltd News

Biocon surges after Malaysian facility gets classified as VAI by the US FDA

Biocon jumped 4.03% to Rs 375.40 after the company said that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins facilities in Johor Bahru, Malaysia as voluntary action indicated (VAI).

13 Jan 2025, 09:34 am

Biocon rises after biosimilars arm gets regulatory approval from Japan Health Authority for Ustekinumab

Biocon added 3.69% to Rs 371.85 after the company said that Biocon Biologics has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for Ustekinumab BS subcutaneous injection.

07 Jan 2025, 09:36 am

Biocon announces board meeting date

On 30 January 2025

04 Jan 2025, 10:07 am

Biocon arm receives approval for Tacrolimus capsules in China

Biocon said that it's wholly owned subsidiary, Biocon Pharma, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China.

03 Jan 2025, 11:35 am

Biocon Biologics completes final remittance under acquisition agreement with Viatris

30 Dec 2024, 10:10 am

Biocon Ltd Stock Analysis

Annual revenue for Biocon Ltd increased by 2.47% to ₹2,320.30 crore in FY 2024 from ₹2,264.30 crore in FY 2023.
Annual Net Profit for Biocon Ltd decreased by 95.81% to ₹119.30 crore in FY 2024 from ₹2,848.40 crore in FY 2023.
Promoter Shareholding in Biocon Ltd remains unchanged by 0.00% in the most recent quarter, from 60.64% in September 2024 to 60.64% in December 2024.
Biocon Ltd delivered a 1-year return of 48.78% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Biocon Ltd share price moved down by 1.37% from its previous close of INR ₹390.55. The latest Biocon Ltd share price is INR ₹385.20.
Biocon Ltd share price today has been at a low of 382.65 and a high of 392.35. Over the past 52 weeks, the Biocon Ltd share price has seen a low of 244.55 and a high of 404.70.

About Biocon Ltd

Biocon Ltd. was established in 1978. It is a leading biopharmaceutical company headquartered in Bengaluru, Karnataka, India. With many decades of experience, Biocon has made strides in developing and manufacturing affordable biosimilars. This also goes for generic formulations, and complex APIs (Active Pharmaceutical Ingredients). The company also offers research services and social initiatives focused on healthcare and education.

Operating in the biopharmaceutical sector, Biocon has carved out a niche for itself with its innovative products. The company’s main offerings include biosimilars such as Insugen, Basalog, and CANMAb. Along with that, they provide generic formulations and novel biologics. These products have helped Biocon establish a strong presence both in India and globally.

Kiran Mazumdar-Shaw is the founder and Executive Chairperson. He has been a driving force behind Biocon’s success. Under her leadership, the company has become one of India’s largest biopharmaceutical firms. However, it is not stated as the biggest player in the industry.
The promoter shareholding is Kiran Mazumdar-Shaw. She holds a substantial stake in the company. She holds a 60.64% stake in the company. Biocon’s registered office is located at 20th KM, Hosur Road, Electronic City, Bengaluru - 560 100, Karnataka, India. The company’s registrar is KFin Technologies Limited.
Key management promoters include:

Kiran Mazumdar-Shaw
Siddharth Mittal
Ravi Rasendra Mazumdar
Eric Vivek Mazumdar
Maleveetil Damodaran

Biocon continues to innovate and expand its product portfolio. It is contributing significantly to the biopharmaceutical sector.

Impact of the Company

Biocon Ltd. is a pioneering biopharmaceutical company based in Bengaluru, Karnataka, India. It has made significant contributions to the global healthcare landscape since its start in 1978. Over the past decades, Biocon has focused on developing affordable biosimilars. It has focused on generic formulations and complex APIs (Active Pharmaceutical Ingredients). It is making essential medicines accessible to a broader population.

Innovative Product Development
Biocon’s commitment to innovation is evident in its diverse product portfolio. This includes biosimilars like Insugen, Basalog, and CANMAb. It also includes novel biologics and generic formulations. These products have enhanced Biocon’s market presence. It has provided cost-effective treatment options for chronic diseases such as diabetes and autoimmune disorders. The company’s focus on biosimilars has positioned it as a key player in the biopharmaceutical sector. It is addressing the growing demand for affordable biologic therapies.

Global Reach and Collaborations
Biocon’s impact extends beyond India, with a significant presence in global markets. The company has established strategic partnerships and collaborations with leading pharmaceutical companies worldwide. It is enhancing its research capabilities and market reach. For instance, Biocon’s collaboration with Mylan has been developing and commercializing biosimilars in international markets. Additionally, Biocon has a licensing agreement with Tabuk Pharmaceutical Manufacturing Company. This was to market its GLP-1 products in the Middle East. This exemplifies its strategic expansion efforts.

Research and Development
Investment in research and development (R&D) is a cornerstone of Biocon’s strategy. The company has allocated many resources to R&D. It focuses on novel biologics and innovative therapies. This commitment has led to the development of cutting-edge treatments. It has positioned Biocon as a leader in biopharmaceutical innovation.

Regulatory Milestones
Biocon’s adherence to stringent regulatory standards has been pivotal in its success. The company’s facilities undergo regular inspections. Global regulatory authorities, including the US FDA do this. Recently, Biocon’s API facility in Bengaluru received four observations from the US FDA. The company is addressing this within the stipulated timeframe. Such regulatory scrutiny ensures that Biocon’s products meet the highest quality standards. It is reinforcing its reputation as a reliable biopharmaceutical manufacturer.

Sustainability and Social Responsibility
Sustainable development is integral to Biocon’s business strategy. The company is committed to creating social and ecological impacts through various initiatives. Biocon’s sustainability efforts include reducing its carbon footprint. It also includes conserving water and promoting renewable energy. Additionally, the Biocon Foundation undertakes numerous healthcare and education initiatives. It is improving the quality of life for underserved communities. These efforts underscore Biocon’s dedication to being a responsible corporate citizen.

Economic Impact
Biocon’s economic contributions are large, generating significant revenue and employment opportunities. Its market reflects its strong financial performance and investor confidence. Strategic acquisitions, product launches, and market expansions have marked the company’s growth. These are contributing to its robust economic footprint.

Challenges and Future Outlook
Despite its successes, Biocon faces challenges such as regulatory hurdles. It faces market competition and the need for continuous innovation. Addressing these challenges requires sustained investment in R&D. It also requires adherence to regulatory standards and strategic market positioning. Looking ahead, Biocon aims to expand its biosimilar portfolio and enhance its global presence. It will continue its focus on affordable healthcare solutions.

Biocon Ltd.’s impact on the biopharmaceutical industry is profound. Global collaborations and commitment to sustainability drive it. The company’s efforts have advanced healthcare. It has contributed to economic growth and social well-being. Biocon continues to steer the complexities of the biopharmaceutical landscape. Its focus on innovation and affordability will remain central to its mission of transforming global healthcare.